BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12753652)

  • 1. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer.
    Cerwenka A; Lanier LL
    Tissue Antigens; 2003 May; 61(5):335-43. PubMed ID: 12753652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for target cell recognition by natural killer cells.
    Diefenbach A; Raulet DH
    Immunol Rev; 2001 Jun; 181():170-84. PubMed ID: 11513138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
    Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
    Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
    Sutherland CL; Chalupny NJ; Cosman D
    Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The innate immune response to tumors and its role in the induction of T-cell immunity.
    Diefenbach A; Raulet DH
    Immunol Rev; 2002 Oct; 188():9-21. PubMed ID: 12445277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.
    Jinushi M; Hodi FS; Dranoff G
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9190-5. PubMed ID: 16754847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligands for natural killer cell receptors: redundancy or specificity.
    Cerwenka A; Lanier LL
    Immunol Rev; 2001 Jun; 181():158-69. PubMed ID: 11513137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of V gamma 9V delta 2 T cells by NKG2D.
    Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
    J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promiscuity and the single receptor: NKG2D.
    Eagle RA; Trowsdale J
    Nat Rev Immunol; 2007 Sep; 7(9):737-44. PubMed ID: 17673918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
    Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
    Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D and Related Immunoreceptors.
    Strong RK; McFarland BJ
    Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors.
    Deng L; Mariuzza RA
    Semin Immunol; 2006 Jun; 18(3):159-66. PubMed ID: 16737824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NKG2D receptor and its ligands-recognition beyond the "missing self"?
    Watzl C
    Microbes Infect; 2003 Jan; 5(1):31-7. PubMed ID: 12593971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
    J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of NKG2D ligand expression on host immune responses.
    Champsaur M; Lanier LL
    Immunol Rev; 2010 May; 235(1):267-85. PubMed ID: 20536569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
    Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
    J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.